5-Bromo-2-Chloro-4′-Ethoxydiphenylmethane CAS 461432-23-5 ʻOihana Kūwaena ʻo Dapagliflozin

ʻO ka wehewehe pōkole:

Inoa: 5-Bromo-2-Chloro-4′-Ethoxydiphenylmethane

Nā huaʻōlelo like: 4-Bromo-1-Chloro-2-(4-Ethoxybenzyl)benzene

CAS: 461432-23-5

Maʻemaʻe: ≥99.0% (HPLC)

ʻAno: Keʻokeʻo i ka Pael Yellow Crystalline Powder

ʻO ka waena o Dapagliflozin (CAS: 461432-26-8) i ka mālama ʻana i ka maʻi diabetes type II

ʻO ke kūlana kiʻekiʻe, ka hana kālepa

Inquiry: alvin@ruifuchem.com


Huahana Huahana

Nā Huahana Pili

Huahana Huahana

wehewehe:

Mea Manufacturer Supply, High Purity, Commercial Production
Dapagliflozin (CAS: 461432-26-8) Nā Kūwaena Pili:
5-Bromo-2-Chlorobenzoic Acid CAS 21739-92-4
5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane CAS 461432-23-5
2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone CAS 32384-65-9

Na Waiwai Kemika:

Inoa Kimia 5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane
Nā huaʻōlelo like 4-Bromo-1-Chloro-2-(4-Ethoxybenzyl)benzene;4-(5-Brom-2-Chlorbenzyl)phenyl-Ethylether;Dapagliflozin Bromo haumia
Helu CAS 461432-23-5
Helu CAT RF-PI447
Kūlana Kūʻai Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā tona
ʻĀpana Molekala C15H14BrClO
Kaumaha Molecular 325.63
Lae hehee 41.0 a 43.0 ℃
Brand ʻO Ruifu Chemical

Nā kikoʻī:

'ikamu Nā kikoʻī
Ka nana aku Keʻokeʻo i ka Pael Melemele Crystalline Pauda
Maʻemaʻe / Kaʻina Hanana ≥99.0% (HPLC)
Wai (KF) ≤0.50%
Huina paumaele ≤1.0%
Kūlana hoʻāʻo ʻOihana Kūlana
Hoʻohana Ka waena o Dapagliflozin (CAS: 461432-26-8), ʻano maʻi diabetes II

Pūʻolo a me ka waiho ʻana:

Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.

Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai.

Pono:

1

FAQ:

Noi:

Hoʻohana ʻia ʻo 4-Bromo-1-Chloro-2-(4-Ethoxybenzyl)benzene (CAS: 461432-23-5) ma ke ʻano he waena i ka synthesis o Dapagliflozin (CAS: 461432-26-8).ʻO Dapagliflozin kahi mea paʻa, koho i ka renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor no ka mālama ʻana i ka maʻi diabetes type 2.ʻO Dapagliflozin kahi lāʻau antidiabetic hou i hoʻomohala pū ʻia e Bristol-Myers Squibb a me AstraZeneca, i ʻae ʻia e ka European Medicines Agency (EMA) ma Nowemapa 12, 2012. Ma Ianuali 8, 2014, ua ʻae ka US Food and Drug Administration (FDA). no ka hoʻohana ʻana i ka mālama ʻana i ka maʻi diabetes type II.

E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou